Working… Menu
Trial record 27 of 159 for:    colon cancer AND Capecitabine AND Fluorouracil

Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00081536
Recruitment Status : Unknown
Verified April 2004 by Aronex Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : April 20, 2004
Last Update Posted : June 24, 2005
Information provided by:
Aronex Pharmaceuticals

Brief Summary:
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and capecitabine in subjects with unresectable, local recurrence or distant metastases of colorectal cancer refractory to 5-FU/leucovorin and irinotecan. In Phase II, the primary objective is to evaluate the response proportion and duration with Aroplatin/capecitabine therapy. Secondary objectives are to evaluate frequency and severity of adverse events.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Drug: Aroplatin (Liposomal NDDP) in combination with capecitabine Phase 1 Phase 2

Detailed Description:

Phase I Primary Objective:

  • Determine the MTD of Aroplatin/capecitabine subjects with unresectable local recurrence or distant metastases of colorectal cancer refractory to 5-FU/LV and irinotecan.

Phase II Primary Objective:

  • Evaluate the response proportion and duration with Aroplatin/capecitabine therapy.

Phase II Secondary Objective:

  • Evaluate the frequency of adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 105 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically confirmed colorectal cancer: unresectable local recurrence or distant metastases;
  • Measurable disease (RECIST criteria);
  • Refractory to 5-FU / leucovorin and irinotecan as described below;
  • No prior therapy with oxaliplatin, any other platinum or capecitabine;
  • ECOG score 0-2 (Karnofsky 100-70%);
  • Life expectancy of greater then or equal to 5 months;
  • Adequate hematopoietic, liver and renal function;
  • Women of child-bearing potential have to practice adequate contraception;
  • Signed written informed consent;
  • Subjects must be willing to be followed during the course of treatment/observation and follow-up.

Refractory metastatic colorectal cancer

The following subjects are regarded refractory to treatment:

  • Those with progression while receiving 5-FU/LV/irinotecan;
  • Those with progression on irinotecan after prior 5-FU/LV treatment;
  • Progression within six months of adjuvant 5-FU/LV/irinotecan;
  • Progression within six months of adjuvant 5-FU/LV followed by progression on irinotecan

Subjects must have received at least one or more commonly used 5-FU/leucovorin and irinotecan regimens. Prior adjuvant therapy is allowed including 5-FU/leucovorin or other fluoropyrimidines except capecitabine and irinotecan.

Exclusion criteria:

  • Previously diagnosed brain metastases if symptomatic and requiring active therapy;
  • Other cancers within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin;
  • Concurrent chemotherapy or immunotherapy;
  • Prior therapy for colorectal cancer within one month of admission to the present study;
  • Primary or secondary immunodeficiency or use of corticosteroids or other immunosuppressive medication;
  • Any serious concomitant medical or mental illness requiring intense therapy and interfering with participation in this study;
  • Women must not be pregnant or breast-feeding;
  • No participation in any clinical trial involving investigational drugs within 1 month from enrollment into the present study.

Layout table for additonal information Identifier: NCT00081536     History of Changes
Other Study ID Numbers: C-726-03
First Posted: April 20, 2004    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: April 2004
Keywords provided by Aronex Pharmaceuticals:
Colorectal Neoplasms
Colorectal Cancer
Colorectal Carcinoma
Colorectal Tumor
Neoplasms, Colorectal
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents